Briacell Therapeutics
BCTX
13 hedge funds and large institutions have $137K invested in Briacell Therapeutics in 2025 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 3 closing their positions.
0.57% more ownership
Funds ownership: 0.09% → 0.66% (+0.57%)
13% less funds holding
Funds holding: 15 → 13 (-2)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
25% less capital invested
Capital invested by funds: $181K → $137K (-$44.5K)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$116K |
| 2 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
+$5.83K |
| 3 |
Morgan Stanley
New York
|
+$1.19K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$683 |
| 5 |
SS
SBI Securities
Tokyo,
Japan
|
+$210 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$116K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$15.3K |
| 3 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$1.43K |
| 4 |
Raymond James Financial
St Petersburg,
Florida
|
-$300 |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$74 |
BCTX Hedge Fund Activity: Q3 2025 in Review
13 of the 7,622 institutional investors tracked by Wall St. Rank reported a position in Briacell Therapeutics (BCTX) for Q3 2025, worth a combined $137K — down 25% from $181K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of BCTX and 1 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 4 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $116K. The largest seller was Sabby Management, exiting entirely with an estimated $116K sold.
- 13 institutional investors held Briacell Therapeutics (BCTX) as of Q3 2025, down from 15 in Q2 2025.
- Funds reported $137K of Briacell Therapeutics stock for Q3 2025, down 25% quarter-over-quarter.
- 1 fund opened new Briacell Therapeutics positions in Q3 2025 and 3 closed out, a net change of -2 holders.
- The largest Briacell Therapeutics buyer in Q3 2025 was Citadel Advisors, an estimated $116K added.
- The largest Briacell Therapeutics seller in Q3 2025 was Sabby Management, an estimated $116K sold.
Based on aggregated 13F filings for Q3 2025.